Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by cd19/cd22 bispecific targeted car t-cell therapy significantly improves survival in relapsed/refractory b-all patients

HIGHLIGHTS

• who: Yunju Ma from the prognosis in, ALLTherefore, we speculated that DAC in combination with fludarabine and cyclophosphamide (FC) as a lymphodepletion regimen may synergize and improve the efficacy of CAR, cell therapy. We retrospectively analyzed , r/r, ALL patients without remission before lymphodepletion treatment who were enrolled in a phase, clinical trial of CD19/ , CAR, cell therapy (NCT03614858) from October , to May , at the First Affiliated Hospital of Soochow University (Additional file, : Figure, ). Fourteen patients received DAC combined with the FC regimen (DAC group) while twelve patients were treated with FC alone (CON group) followed by . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.